PDCD1LG2 and neoplasm: Pembrolizumab, a human monoclonal anti-PD-1 antibody, inhibits the interaction of PD-1 with PD-L1/ programmed cell death ligand-2 (PD-L2), thereby promoting an immunologic response by T cells against tumor cells.